Your session is about to expire
← Back to Search
MRx0518 for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new drug, MRx0518, in combination with pembrolizumab to see if it is safe and effective in treating patients with solid tumors.
- Cancer
- Non-Small Cell Lung Cancer
- Kidney Cancer
- Melanoma
- Bladder Cancer
- Solid Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
In how many different venues is this research taking place?
"Five medical facilities are currently enrolling for this clinical trial, namely the University of Kansas Medical Center in Kansas City, Houston Methodist Cancer Center in Houston and Summit Cancer Center in Spokane. Additionally, there are five other locations participating across the US."
What ailment is MRx0518 normally utilized to treat?
"MRx0518 is an effective treatment for malignant neoplasms, inoperable melanoma, and cases of microsatellite instability high."
Is this trial currently accessible for participants?
"This particular clinical trial has since ended its recruitment process. It was first posted on the 10th of January 2019, and last updated on 5 July 2022. Nevertheless, if you're looking for other studies related to melanoma, there are 4209 trials recruiting patients; or alternatively 961 studies actively searching for participants with MRx0518."
Can you provide insight into any other experiments involving MRx0518?
"Currently, 961 clinical trials are collecting data on the efficacy of MRx0518 with 122 Phase 3 studies. Houston, Texas is at the centre of many of these research programs but there are 35731 different locations offering this medication to participants."
How many individuals are actively engaged in this clinical experiment?
"At this time, recruitment for this trial has been suspended. It was first listed on the 10th of January 2019 and last modified on July 5th 2022. There are presently 4209 studies recruiting patients with melanoma and 961 trials seeking participants for treatment with MRx0518."
Share this study with friends
Copy Link
Messenger